Citi analyst Matthew Heimermann upgraded Marsh McLennan (MRSH) to Buy from Neutral with an unchanged price target of $200. The firm upgraded four names in the insurance broker group citing valuation. Cyclical growth pressures should ease over the next few quarters, creating a “systemic return opportunity in the sector,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSH:
- Marsh McLennan’s Oliver Wyman enters agreement to acquire CR3 Partners
- Marsh McLennan to acquire TriBridge Partners, terms not disclosed
- Marsh McLennan enters multiyear partnership with Formula 1
- Marsh McLennan price target raised to $203 from $200 at Keefe Bruyette
- Marsh & McLennan Warns of Broad Risk Exposure That Could Materially Impact Financial Performance